Stay updated on Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial
Sign up to get notified when there's something new on the Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial page.

Latest updates to the Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial page
- Check2 days agoChange DetectedThe page now indicates that recruitment is no longer open, and new sections for How to Read a Study Record, Common Questions, and How to Join a Study have been added. The Intervention/Treatment header label was updated from Intervention / Treatment, and the revision tag was changed to v3.6.0.SummaryDifference0.1%

- Check9 days agoChange DetectedA new revision tag Revision: v3.5.5 was added, replacing Revision: v3.5.4. This reflects a newer version of the page template/document without altering substantive content.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page revision was updated from v3.5.3 to v3.5.4, indicating a small administrative update to the study record. There are no visible changes to the study details or layout reflected by this update.SummaryDifference0.0%

- Check37 days agoChange DetectedThe Taiwan location entry was updated to reflect Taoyuan as the city instead of Taoyuan District, aligning the site listing with standard naming in the study's locations.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page footer’s software/content revision label was updated from **v3.5.2** to **v3.5.3**.SummaryDifference0.0%

- Check58 days agoChange DetectedThe collaborator name has been updated to Ono Pharmaceutical Co., Ltd and the revision version changed from v3.5.0 to v3.5.2.SummaryDifference0.0%

Stay in the know with updates to Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial page.